The ability to act upon more than one disease and disorder has led to the GLP-1 analogues market has been getting a tremendous boost globally in recent times.New York, USA, Nov. 19, 2024 (GLOBE ...

- DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% ...

Doctors say GLP-1s are not approved as a prevention method for menopause weight gain. Here's how to manage the weight changes ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and ...

A study found that GLP-1 RA use is linked to risks for retained gastric contents during single endoscopic procedures but not ...

The fund posted returns of 6.75% (Institutional shares) and 6.68%(Investor A shares, without sales charge) for the third ...

By Dr. Sushama R. Chaphalkar, PhD. Research shows how common diabetes medications are transforming asthma care by reducing ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).